Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A clinical trial to test if the drug ertugliflozin is safe and effective when compared to placebo in patients with Type 2 Diabetes whose sugar levels are not well controlled by their current treatment with Metaformin and Sitagliptin
After 26 weeks, in subjects with T2DM and inadequate glycemic control on treatment with metformin ≥1500 mg/day and sitagliptin 100 mg q.d.: 1) To assess the A1C-lowering efficacy of the addition of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co
Update Il y a 5 ans
TECOS: A Cardiovascular Outcomes Study for Type 2 Diabetes
To compare the impact of including sitagliptin as part of usual care vs. usual care without sitagliptin on CV outcomes as measured by the time to first event in the primary CV composite endpoint of CV...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp
Update Il y a 5 ans
A Clinical Trial to Study the Safety and Effectiveness of MK-5172 with Ribavirin in Patients with Hepatitis C Ensayo clínico para estudiar la eficacia y la seguridad de MK 5172 en combinación con ribavirina (RBV) en sujetos con hepatitis C
1) To evaluate the efficacy of each treatment arm of MK-5172 in combination with RBV as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A clinical study of Pembrolizumab plus axitinib vs. sunitinib in advanced kidney cancer
1. To evaluate and compare PFS per RECIST 1.1 as assessed by BICR in subjects. treated with pembrolizumab plus axitinib versus sunitinib monotherapy. 2. To evaluate and compare OS in subjects treated ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Estudio multicéntrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con Prevenar 13 en lactantes sanos";"A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13 in Healthy Infants
(1) Objetivo: demostrar que la vacuna antineumocócica conjugada 15 valente (V114) con aluminio como adyuvante o V114 sin adyuvante no es inferior a la vacuna antineumocócica conjugada 13 valente (Prev...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Estudio Global VerICiguaT en sujetos con insuficiencia cardíaca con fracción de eyección reducida (Victoria)
To evaluate the efficacy of the oral soluble guanylate cyclase (sGC) stimulator MK-1242 (vericiguat) in comparison to placebo on a background of standard of care in increasing the time to first occurr...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubicin and Docetaxel in Breast Cancer Patients
1) To compare DSN, defined as the number of days with ANC < 0.5 x 109/L, during Cycle 1, in patients with breast cancer receiving MK-4214 or Neupogen™ as adjunct to chemotherapy with doxorubicin in co...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
MK- 0542B-PN 143 Research study that will test the safety & efficacy of combining extended release niacin + laropiprant + simvastatin (MK-0524B) in the management of cholesterol levels
Evaluate the LDL-C-lowering effects of ERN/LRPT/SIM 2 g/20 mg compared to ERN/LRPT 2 g coadministered with simvastatin 20 mg. Hypothesis: ERN/LRPT/SIM 2 g/20 mg is equivalent to ERN/LRPT 2 g coadmini...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Single Dose Study to Assess the Biocomparison of MK-8669 in Subjects
To evaluate the whole blood pharmacokinetics and comparative bioavailability (AUC0-∞, Cmax, Tmax and apparent t1/2) of 2 new granule formulations of ridaforolimus compared to the provisional market 10...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp
Update Il y a 5 ans
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
Main objective: To assess the safety and tolerability of inactivated VZV vaccine in recipients of autologous HCT and to assess the impact of inactivated VZV vaccine on the development of HZ following...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
4
5
6
7
8
9
10
11
12
13
Next